leisure time -WSS

leisure time

author：focus 2025-09-06 04:33:59 - browse：86971

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Penis shrinkage, a side effect of prostate cancer surgery, is temporary

WSS

The wait for US passports is creating travel purgatory and snarling summer plans

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Snackable artificial intelligence, expert AI, and the pharma industry

Ethical issues complicate the benefits of medical crowdfunding

Use doctors trained outside the U.S. to ease the physician shortage

How to fix cancer clinical trials' diversity problem

entertainment

leisure time

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

House transparency, PBM reform bill gains bipartisan support

BioMarin wins approval for gene therapy to treat hemophilia A

STAT wants to know your pick for a great summer read or listen

Trump demands the U.S. pay no more for drugs than other countries … again

How to fix cancer clinical trials' diversity problem

Sports medicine is finally prioritizing gender equality

Drug cartel violence flares in western Mexico after vigilante leader's killing

How one medical school became remarkably diverse

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

knowledge

What American doctors can learn from their Israeli counterparts

The (many) problems with a new study criticizing cancer screening

Snackable artificial intelligence, expert AI, and the pharma industry

Advances in CAR

A new House health package & hospitals’ new site

Drug cartel violence flares in western Mexico after vigilante leader's killing

focus

Wikipedia

hotspot

hotspot